Minority report by Government Senators
The Government
believes that the Gene Technology Bill
2000 adequately meets its objectives in designing a key piece of
legislation that aims to protect both the public health and safety of Australians
and the environment from the risks associated with gene technology. The Bill
also has strong support from the States and Territories.
Vast consultation
across the board, from organisations, to individuals to government has occurred
in structuring the Bill as it stands. This high degree of consultation is
unprecedented and any alteration now has the very real potential to jeopardise
its implementation.
Government Senators
would make the following observations about some of the recommendations that have
the potential for such uncertainty.
Chapter 3
Risk assessment
provisions currently in the Bill give sufficient weight to the consideration of
the impact of the release of GMOs into the environment especially given
Australia’s unique flora and fauna and mindful of maintaining Australia’s
biodiversity. Measures to achieve this outcome include the establishment of a
statutory officer (the Gene Technology Regulator), the prohibition of people
from dealing with GMOs except in certain circumstances, the establishment of a
scheme to assess human health and environmental risks in various dealings with
GMOs, provision for monitoring and enforcement of the legislation, and the
establishment of three key advisory committees each dealing with different
aspects of gene technology.
Commercial in
confidence provisions in the Bill are designed in order not to compromise the
objectives of the Bill or dilute the transparency of the regulatory regime. If
a licence applicant desires that certain information be protected, the GTR must
assess each case individually and make a decision. If the GTR decides the
release of information may be detrimental to an applicant, he or she may decide
that the public good outweighs the interests of the applicant.
Independent review
of the Act in three years is not practical for, as with any new scheme time is
required to implement it fully. The Government is not amenable to any review
before five years. After this time it is expected that review can more
competently be performed after the legislation has been given sufficient time
to be bedded down.
Chapter 4
The Committee
recommendation concerning financial interest provisions overlooks provisions
that already exist in the Bill. Strong conflict of interest provisions ensure
that the Regulator is required to disclose to the Minister all interests,
pecuniary or otherwise, that may conflict with the performance of his or her
functions.
Precluding an
individual who has worked for a regulated entity from holding the office of the
Gene Technology Regulator for a two-year period is problematical. By virtue of
the fact that this field is limited, this recommendation is totally
impractical. As long as an individual declares his or her interests, an
application must be assessed on a merit only basis.
The Government
Senators are not opposed to the Bill being amended to require quarterly
reporting, however provisions for reporting relevant breaches of licence
conditions are already present requirements in the Bill.
The Government
Senators however, are entirely opposed
to the notion of the establishment of the Regulator as a Statutory Authority
consisting of three people who will take the ultimate responsibility for
decision making. This proposition is economically unviable, given the size of
the GTR (50 people). Establishing the office as a Statutory Authority would
cost at least an additional $500,000 a year. It would also be impossible to
quantify the gain in establishing a Statutory Authority, given the high level
of independence already achieved within the Bill.
Consideration of the
feasibility of introducing a ‘one-stop shop’ model having regard to the
operational effectiveness of the proposed ‘gap-filler’ arrangements is already
something the Government is attempting to do. It is desirable that the arrangements
as they stand encourage the ‘one stop shop’ concept however, continuing to be
mindful that different authorities look after different areas of
responsibility.
The Bill does
creates a ‘one-stop shop’ for biosafety assessment of all GMOs and GM products
by establishing a centralised national regulator who carries out risk
assessment of all GMOs and GM products. This allows for the GTR to act as a
centralised area of expertise that will make advice on GM products to other
regulators. It also minimises duplication by employing strategies to improve
the interface between regulators.
Significantly, this
method will be able to be implemented in a shorter timeframe than a complex
single agency to regulate all GMOs and GM products, which would take a great deal
longer to establish and would fail to meet community and industry demand for a
fully operational GTR by 2001.
In May 2000, the
Federal Government established the Regulatory Reform Taskforce within the
Department of Health and Aged Care in response to calls from consumers and
industry for better coordination of public health regulators. The Taskforce is
examining the current administrative arrangements for this regulation at
Commonwealth level and will identify ways to improve it.
The Committee
acknowledges that the proposed structure provides the option that ensures all
aspects of the production, manufacture and sale of GMOs and GM products are
regulated and that there are no ‘gaps’ in regulatory coverage. The system in
the Bill guarantees the Regulator either directly regulates or provides advice
to specific regulators on all GMOs and GM products.
The Government
Senators believe that the assessment of environmental risks can be better met
through the Gene Technology Bill rather than the Environment Protection and Biodiversity Conservation Act 1999. The
objectives of the Bill are to meet environmental safety concerns in conjunction
with human health and safety provisions. The GTR has been placed under the
Health portfolio in this context. The issue of GTR flexibility is also a major
point and risk assessments should be performed on a case by case basis whereby
the Regulator must be afforded the flexibility to assess each case
individually.
Listing of broad
categories of risk once again addresses the notion of flexibility for each
application on a case by case basis. The absence of prescriptive categories of
risk was intentional because of the fact that there are so many varying types
of GMOs that the Regulator will be required to assess. There are however, some
broad categories of risk prescribed in the regulations, which the Regulator may
take into account.
The Committee
believes that the Regulator, when setting licence conditions may satisfy him or
herself that applicants have made provisions with insurers for suitable
coverage to protect them against the risks associated with the dealings.
Mandatory review or
renewal of licences granted by the Regulator is provided for in the Bill and
there is capacity for review at any juncture or time.
The Committee agrees
that the ultimate responsibility lies with the applicant to provide adequate
scientific support for its case to the Regulator. The Regulator is then obliged
to make a decision based on independent assessment and evaluation of data
provided by the applicant and then further through the public and committee
processes. The Regulator will ensure, as much as is possible, that
contamination of non-genetically modified produce or land cannot occur.
The Bill provides a
number of requirements afforded to the Regulator to monitor compliance with the
legislation. Provisions include the imposition of conditions, monitoring of
compliance with these provisions, obligations to report, investigative powers
addressing alleged breaches, enforcement powers and penalties.
Recommendations
concerning licence holders to guarantee compliance is not necessary given
companies will also monitor progress with dealings. The Regulator will also
have the power to impose conditions to limit contamination and vary a licence,
including imposing additional conditions or confiscating or altering existing
conditions.
Furthermore, the
Regulator is provided by the legislation with the following ways in which to
monitor compliance with conditions. The GTR may require regular auditing to be
undertaken by a licence holder and reporting to be made to the Regulator.
Routine audits may also be undertaken, as might ‘on-the-spot’ inspections or
audits of dealings with GMOs.
The legislation
allows for the Regulator to appoint inspectors for the purposes of
investigating alleged breaches. In the event of non-compliance, the legislation
describes a range of investigative powers that may be used by inspectors for
determining whether a breach has indeed occurred.
Inspection powers
are similar to those granted to the Australian Federal Police, Customs agents
and inspectors appointed under the Therapeutic Goods Act and are substantial,
and consistent with Commonwealth criminal law policy.
The 1999 Draft Bill
has been amended to respond to requirement for monetary penalties in the
instance of breaches of licence conditions, to reflect concerns that arose in
previous consultation.
Provisions for
penalties are clear and the Government believes suitably fitting. Offence
provisions and penalties are consistent with criminal law policy and are
significant in comparison to other regulatory schemes. It is clear that the
Government has adequately introduced strict liability offences to the Bill. In
the case of a breach of condition that causes significant damage to the health
and safety of people or the environment, there are two alternative monetary
penalties that may be pursued.
While the Government
Senators recognise that there is a degree of anxiety about the issue of cost
recovery, the policy is one hundred percent cost recovery. A KPMG Inquiry has
determined that the annual cost for the first couple of years will be
approximately $7.8 million. The Productivity Commission is in the process of
looking at this issue and a draft report is due in March 2001.
Chapter 5
There is a
requirement in the legislation that cross membership of the three advisory
committees exist however, the Government Senators are not in favour of
increasing the role of either the Community Consultative Group or the Ethics
Committee.
The Committee believes
that the Gene Technology Technical Advisory Committee should essentially be
comprised of members who are capable of providing to the Ministerial Council
and the Regulator scientific information and advice.
The function of the
Gene Technology Community Consultative Group is to provide advice on matters of
‘general concern’ and will be consulted only in relation to general principles
or guidelines, not in relation to specific decisions.
An increased role
for either or both of these Committees would be entirely detrimental to the
science-based decision making process. It would also be contrary to every other
country’s risk assessment policy and furthermore creates absolute uncertainty
in the process. Other foreseeable problems include unacceptable delays, increased
costs for the OGTR and the possibility of leakage of in-confidence information.
Consultation by the
Ministerial Council of the three Committees when issuing policy guidelines is
both impractical and unworkable. The Ministerial Council is essentially
political. This measure would also contribute to implementing another laborious
procedure. The Bill as it is, is exceptionally consultative and need not be
more so.
As a result of other
mechanisms in the Bill, there is adequate opportunity for community input on
individual applications. This high level of community involvement in decision
making is unprecedented in most existing regimes.
It is not necessary
to incur additional costs and resources to duplicate the process by allowing
the Gene Technology Community Consultative Group to examine individual
applications.
While the Bill does
not directly provide for third party appeal, mechanisms exist for appeal. There
are adequate opportunities for third parties to express discontent throughout
the open process of assessment. It was also considered appropriate by the
Government in conjunction with the States and Territories, that the right to
review by the AAT to those directly affected by a decision would be limited.
This was because of a number of issues including the concerns of the time and
cost resources that would have to be donated to review after an already lengthy
consultation process.
In addition, by
limiting review to those immediately affected, the prospect of vexatious
appeals is significantly reduced or eliminated and is consistent with
Commonwealth policy. This is also consistent with similar legislation and hence
the Government Senators believe is more than appropriate given the lengthy
consultative process.
Also, by allowing
the States appeal to the AAT, individuals are able to appeal to the State to
make a representation on their behalf to contest the merits of a decision made
by the Regulator.
Chapter 6
Provisions in the
Bill requiring the Regulator to accept State or Territory viewpoints to prevent
the release of GMOs within their jurisdictions has already been taken into
account, in part through the States and Territories role in the Ministerial
Council. It is imperative that the integrity of a strong national regulatory
system be maintained - it cannot afford to be fragmented.
Government Senators
believe it is acceptable to allow the results of breaches to be made publicly
available. However, issues such as the cost and manpower required to audit and
publicly report all dealings are
impractical. Not only would this be expensive and time consuming, it would not
allow for the flexibility to spend more time on high-risk GMO dealings.
Conclusion
This legislation is
being introduced to coordinate a national regulatory system that is
transparent, open and heeds stringent regulatory processes. The emergence of
growing debate about gene technology and its consequences has highlighted the
urgent need for a piece of legislation such as the Gene Technology Bill 2000 and its implementation is well timed.
The community at
large has been extensively consulted, as have the States and Territories.
The Government
Senators strongly believe that measures in the Bill ensure that all aspects
have been fully addressed in the objectives set out. We also believe that an
independent and rigorous system needs to be implemented in as timely a fashion
as possible. Any alteration to the Bill at this point is likely to severely
jeopardise this occurring.
We recommend that
the Bill proceed as soon as possible in unamended form.
Senator Sue Knowles,
Deputy Chairman (LP, Western
Australia)
Senator
Tsebin Tchen (LP,
Victoria)